FDA Grants Approval for Lurasidone Hydrochloride ANDA208028
The FDA has granted approval for ANDA208028, a generic version of Lurasidone Hydrochloride, submitted by InvaGen Pharmaceuticals.
Company
InvaGen Pharmaceuticals
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of a generic version of Lurasidone Hydrochloride by InvaGen Pharmaceuticals signifies increased competition in the antipsychotic market. This could lead to pricing pressures and shifts in market share that require strategic reassessment by existing players.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from InvaGen and competitors.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.